Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use ...

French biotech Valneva has secured marketing approval in the UK for its chikungunya vaccine, Ixchiq (chikungunya vaccine), ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya ...

The world’s first vaccine for mosquito-borne chikungunya virus has been approved by the UK’s Medicines and Healthcare ...

Valneva (VALN) stock gained as its chikungunya vaccine receives marketing authorization in the U.K., expanding the single-dose shot's global reach. Read more here.

Valneva has received Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first - and only - Chikungunya vaccine, IXCHIQ. The single-dose vaccine is ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 February 2025, approved the vaccine chikungunya vaccine (live) (brand name ...